Woringer-Kolopp (Pagetoid Reticulosis) disease successful response to bexarotene gel.
Woringer-Kolopp (WK) is a rare subtype of cutaneous T-cell lymphoma (CTCL) with limited treatment options. Bexarotene gel is a topical retinoid used in the treatment of CTCL. This report describes three female patients (mean age 66 years) with WK disease who had an effective treatment response to bexarotene 1% gel. This treatment could provide a safe alternative to other current treatment modalities which have higher risks of potential adverse effects and lack of access to other conventional treatments such as light therapy.
Dermatology, NEA Baptist Clinic, Jonesboro, Arkansas.
Johnathan
J
Ledet
Department of Dermatology, University of Alabama at Birmingham, EFH 414 1530 3rd Ave., South Birmingham, Alabama.
Vlada
V
Groysman
Department of Dermatology, University of Alabama at Birmingham, EFH 414 1530 3rd Ave., South Birmingham, Alabama.
Naveed
N
Sami
D000279:Administration, Cutaneous; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077610:Bexarotene; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D005260:Female; D005782:Gels; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D056267:Pagetoid Reticulosis / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D012878:Skin Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005782:Gels; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene
inflammatory disorders; neoplasms-malignant; therapy-topical